Orforglipron (Foundayo)

Orforglipron is a real, regulated drug with clinical trial data behind its approved use, available only by prescription. This page describes its approved use and standard prescribing information — that's public medical information about a regulated drug, not personalized medical advice. Talk to your doctor about whether it's appropriate for you.

Strictly speaking, orforglipron is not a peptide — it's a small molecule taken by mouth, chemically unrelated to the injectable GLP-1 peptides like semaglutide and tirzepatide elsewhere in this tier. We include it here because it works through the same GLP-1 receptor mechanism and belongs in the same approved-medication conversation, not because it's structurally a peptide.

Orforglipron is a non-peptide small-molecule GLP-1 receptor agonist — it activates the same receptor as injectable GLP-1 drugs, stimulating glucose-dependent insulin release, suppressing glucagon, slowing gastric emptying, and acting on appetite centers in the brain. Because it's a small molecule rather than a peptide, it survives digestion well enough to be taken as a standard pill, with no food or water timing restrictions — unlike earlier oral GLP-1 tablets that required specific fasting conditions to absorb properly.

The FDA approved Foundayo (orforglipron) on April 1, 2026, for chronic weight management in adults with obesity, or overweight with at least one weight-related condition, alongside diet and exercise. Approval was supported by the ATTAIN-1 Phase 3 trial, in which adults on the highest studied dose lost an average of roughly 27 pounds. It is currently approved for weight management only — not for type 2 diabetes, though Eli Lilly has diabetes trials underway.

Eli Lilly — FDA Approval Announcement →

Like injectable GLP-1 drugs, orforglipron is titrated up gradually to reduce GI side effects, starting at a low non-therapeutic dose and stepping up over several weeks to a maintenance dose set by a prescriber. It's taken once daily as a tablet, with no requirement to take it on an empty stomach or wait to eat or drink afterward — a practical difference from Rybelsus (oral semaglutide). This is general public prescribing information, not a personalized recommendation — your prescriber sets your actual dose and schedule.

As a GLP-1 receptor agonist, orforglipron carries the same class boxed warning for thyroid C-cell tumors observed in rodent studies (human relevance not established); it's contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Other risks include pancreatitis, gallbladder disease, and hypoglycemia when combined with insulin or sulfonylureas. The most common side effects are gastrointestinal — nausea, diarrhea, vomiting, and constipation — especially during dose increases.

AJMC — FDA Approves Lilly's Oral GLP-1 Orforglipron for Obesity